WOBURN, Mass. , May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass. , April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest
WOBURN, Mass. , March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck ® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).
WOBURN, Mass. , March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022 . “We have been pleased by the positive response to Quell
WOBURN, Mass. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative
WOBURN, Mass. , Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024 . The Company will host a conference call at 8:00
WOBURN, Mass. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic
WOBURN, Mass. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in
WOBURN, Mass. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID.
WOBURN, Mass. , Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH -funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a